Safety and efficacy study of oral metronomic capecitabine combined with pyrotinib in HER2-positive metastatic breast cancer: A phase II trial

Purpose: To analyze the safety and efficacy of orally administered metronomic capecitabine plus pyrotinib in HER2 positive metastatic breast cancer (MBC) patients, we conducted a prospective phase II study with a single-arm design. Methods: HER2 positive patients received oral metronomic capecitabin...

Ful tanımlama

Detaylı Bibliyografya

Asıl Yazarlar:	Maiyue He, Jiaxuan Liu, Zijing Wang, Fei Ma, Jiayu Wang, Pin Zhang, Qing Li, Peng Yuan, Yang Luo, Ying Fan, Hongnan Mo, Bo Lan, Qiao Li, Binghe Xu
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Elsevier 2023-12-01
Seri Bilgileri:	Breast
Konular:	Phase II study Metastatic breast cancer HER2-Positive pyrotinib capecitabine metronomic chemotherapy
Online Erişim:	http://www.sciencedirect.com/science/article/pii/S096097762300557X
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!